Man on a Mission
This article was originally published in RPM Report
Executive Summary
Congressional Budget Office director Peter Orszag is becoming the apostle of comparative effectiveness research. Orszag believes a national effort will reduce health care costs over the long term-and he's telling anyone who will listen.
You may also be interested in...
Health Care Reform: Plan for Quick Action Dashed By Daschle Withdrawal
The withdrawal of Tom Daschle from consideration as HHS Secretary means there won't be a single focus for health care policy during the upcoming health care reform debate. Can two powerful Democratic legislators and the Obama budget team fill the void?
The Value Proposition: Why Pharma Should Embrace Comparative Effectiveness
A greater investment in comparative effectiveness research appears inevitable, whether or not Congress creates a federally funded agency to conduct head-to-head trials. The Vytorin debacle is only the most recent reason why industry is wary. But there are steps pharma can take to prepare for the next big thing in health care policy. Despite Vytorin, Merck is one of the companies leading the way.
The Value Proposition: Why Pharma Should Embrace Comparative Effectiveness
A greater investment in comparative effectiveness research appears inevitable, whether or not Congress creates a federally funded agency to conduct head-to-head trials. The Vytorin debacle is only the most recent reason why industry is wary. But there are steps pharma can take to prepare for the next big thing in health care policy. Despite Vytorin, Merck is one of the companies leading the way.